Jefferies Financial Group Inc. operates as an investment banking and capital markets firm in the Americas, Europe, the Middle East, and the Asia-Pacific. The company operates in two segments, Investment Banking and Capital Markets, and Asset Management. It provides investment banking, advisory services with respect to mergers or acquisitions, debt financing, restructurings or recapitalizations, and private capital advisory transactions; underwriting and placement services related to corporate debt, municipal bonds, mortgage-backed and asset-backed securities, equity and equity-linked securities, and loan syndication services; and corporate lending services. The company also offers financing, securities lending, and other prime brokerage services; equities research, sales, and trading services; wealth management services; and online foreign exchange trading services. In addition, it provides investment grade distressed debt securities, U.S. and European government and agency securities, municipal bonds, leveraged loans, emerging markets debt, and interest rate and credit index derivative products; and manages and offers services to a diverse group of alternative asset management platforms across a spectrum of investment strategies and asset classes. The company was formerly known as Leucadia National Corporation and changed its name to Jefferies Financial Group Inc. in May 2018. Jefferies Financial Group Inc. was founded in 1962 and is headquartered in New York, New York.

Jefferies Financial Group Inc.

Wall Street analysts expect Jefferies (JEF) to post quarterly earnings of $0.83 per share in its upcoming report, which indicates a year-over-year decline of 21%. Revenues are expected to be $1.93 billion, down 1.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Jefferies metrics that are routinely monitored and predicted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Revenues by Source- Total Asset Management Net revenues' will likely reach $94.31 million. The estimate points to a change of -70% from the year-ago quarter.
The consensus among analysts is that 'Net Revenues by Source- Total Investment Banking and Capital Markets Net revenues' will reach $1.86 billion. The estimate points to a change of +13.8% from the year-ago quarter.
The average prediction of analysts places 'Net Revenues by Source- Total Asset Management Net revenues- Investment return' at -$8.54 million. The estimate indicates a year-over-year change of -108.4%.
The collective assessment of analysts points to an estimated 'Net Revenues by Source- Total Capital Markets' of $681.29 million. The estimate indicates a change of +4.5% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Revenues by Source- Total Capital Markets- Equities' should arrive at $441.58 million. The estimate points to a change of +7.5% from the year-ago quarter.
Analysts expect 'Net Revenues by Source- Total Capital Markets- Fixed income' to come in at $239.72 million. The estimate suggests a change of -0.5% year over year.
Analysts' assessment points toward 'Net Revenues by Source- Total Investment Banking- Total underwriting- Advisory' reaching $637.79 million. The estimate points to a change of +6.9% from the year-ago quarter.
The consensus estimate for 'Net Revenues by Source- Total Investment Banking- Other investment banking' stands at $30.00 million. The estimate indicates a year-over-year change of +9.3%.
Analysts forecast 'Net Revenues by Source- Total Investment Banking' to reach $1.18 billion. The estimate indicates a year-over-year change of +19.9%.
According to the collective judgment of analysts, 'Net Revenues by Source- Total Investment Banking- Total underwriting- Debt underwriting' should come in at $227.88 million. The estimate indicates a year-over-year change of +32.9%.
Analysts predict that the 'Net Revenues by Source- Total Investment Banking- Total underwriting- Equity underwriting' will reach $287.91 million. The estimate indicates a change of +50.6% from the prior-year quarter.
It is projected by analysts that the 'Net Revenues by Source- Total Investment Banking- Total underwriting' will reach $515.79 million. The estimate indicates a year-over-year change of +42.2%.
View all Key Company Metrics for Jefferies here>>>
Shares of Jefferies have experienced a change of +10.5% in the past month compared to the +0.8% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), JEF is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Free Report: Profiting from the 2nd Wave of AI Explosion
The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.
Investors who bought shares like Nvidia at the right time have had a shot at huge gains.
But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.
Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.
Access AI Boom 2.0 now, absolutely free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Jefferies (JEF) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Key Points
It wasn't because of any news coming from the biotech.
Rather, a rival's setback brought the bulls into its stock.
A competitor's setback was Xeris Biopharma's (NASDAQ: XERS) gain on Hump Day. On news that a potential commercial threat to one of its three commercialized drugs had been neutralized (at least for now), investors piled into Xeris stock, sending it to a more than 7% price gain. A bullish analyst note reinforced this positive sentiment.
A fateful FDA decision
That would-be rival is Xeris's fellow biotech Corcept Therapeutics. Wednesday morning, the company announced that the U.S. Food and Drug Administration (FDA) had not approved its relacorilant, a medication used to treat hypertension (high blood pressure) associated with the hormonal disorder hypercortisolism, also known as Cushing's syndrome.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
In the FDA's complete response letter, Corcept stated in a press release that the regulator cited the lack of additional evidence of the drug's effectiveness as a key reason behind its decision. Corcept has vowed to continue attempting to get the treatment approved; however, this will likely necessitate more clinical trials (which can be lengthy and expensive).
The rally in Xeris stock was largely due to a sense of relief. After all, the company's Recorlev -- originally developed by Strongbridge Biopharma, which Xeris acquired in 2021 -- earned FDA approval for the treatment of Cushing's syndrome at the end of that year. This well-established medication, then, won't have to contend with an upstart.
Triple play?
This was the crux of the analyst update, published by Jefferies's Glen Santangelo that morning. In reiterating his buy recommendation and $10 price target on Xeris, according to reports, the analyst wrote that the addressable market for Cushing's disease should continue to grow, with the company benefiting more than it would have if Corcept's drug had won approval.
According to Santangelo's calculations, the current $1 billion U.S. market could triple by 2030 if awareness of the disorder increases sufficiently.
That might be somewhat optimistic, but Corcept's loss is almost indisputably a gain for Xeris. I'd be optimistic about the company's future, too.
Should you buy stock in Xeris Biopharma right now?
Before you buy stock in Xeris Biopharma, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Xeris Biopharma wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $505,749!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,149,658!*
Now, it’s worth noting Stock Advisor’s total average return is 979% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of December 31, 2025.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Corcept Therapeutics and Jefferies Financial Group. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday

Key Points
One analyst believes the company's Filspari has blockbuster potential if it earns FDA approval for a new indication.
A decision on that should come very shortly.
The stock of commercial-stage biotech Travere Therapeutics (NASDAQ: TVTX) barreled into the late holiday period in style. On a pair of new analyst notes covering the company, investors piled into its shares to leave them with an almost 14% gain on Hump Day.
Buyout potential
The first of those two updates was authored by Jefferies's Maury Raycroft. He flagged five biotechs as being particularly juicy takeover candidates in 2026, and Travere made the list. The pundit singled out the company's Filspari as being a choice asset, writing that it could be a blockbuster drug for its developer.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
The drug has been submitted for approval by the U.S. Food and Drug Administration (FDA) for the treatment of focal segmental glomerulosclerosis (FSGS), a kidney disorder. The regulator set Jan. 13, 2026, as the deadline for its decision.
In early 2024, Travere won full approval from the American regulator for Filspari to treat another kidney affliction, immunoglobulin A nephropathy (IgAN).
Indications are good for the new indication, analyst says
On Wednesday morning, Cantor Fitzgerald published an update on Travere, stating that the FDA was signaling potential approval of Filspari. According to reports, Cantor Fitzgerald believes the agency appears to have some flexibility in approving the drug, which bodes well for its future.
The latest indications, then, seem to be quite positive for Travere's kidney treatment. Although Raycroft's take is an interesting one, I wouldn't invest in Travere solely on the prospect of a buyout by a strategic investor. Rather, I'd be bullish on the company if I believed the drug could reach, or at least approach, blockbuster status.
Should you buy stock in Travere Therapeutics right now?
Before you buy stock in Travere Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Travere Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $504,239!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,159,896!*
Now, it’s worth noting Stock Advisor’s total average return is 985% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of December 24, 2025.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Jefferies Financial Group. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

Key Points
Investor excitement around artificial intelligence (AI) has led many stocks to climb faster than their fundamentals support.
These three stocks still offer compelling value, with growth driven by advancements in artificial intelligence across software and hardware.
Recent analyst price targets present the case for significant upside for each of them.
Few trends have had a bigger impact on the stock market than artificial intelligence (AI). Some of the biggest tech companies tied to the trend continued to lead the stock market higher in 2025, even after producing phenomenal gains in 2023 and 2024. Many popular AI stocks appear quite expensive after posting strong growth for three straight years. But analysts still see plenty of upsides for a handful of companies riding the AI wave.
Here are three AI stocks with great upside in 2026, with select analysts' price targets suggesting as much as 88% upside for the year.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
1. Adobe (41% implied upside)
Adobe (NASDAQ: ADBE) stock has struggled in recent years, as many investors are concerned that AI will negatively impact its core photo and video editing software. Meanwhile, the company continues to produce solid operating results, steadily growing its top line through both customer acquisition and increased pricing. Both of those improving metrics are actually bolstered by Adobe's efforts to incorporate AI into its products.
The company has seen strong adoption of Adobe Express since launching the freemium software in 2021. It serves as an important funnel to its premium Creative Cloud package, as well as a source of revenue. Management says it saw "significant" MAU growth last quarter, fueled by new AI Assistant features for content creation and editing.
Overall, Adobe's entire portfolio of freemium offerings counts over 70 million users, and overall MAU growth across Acrobat, Creative Cloud, Express, and Firefly exceeded 15% last quarter.
Management's outlook for 2026 called for just over 9% revenue growth, but digging deeper into Adobe's financial results suggests it could outperform that forecast. Annual recurring revenue for 2025 climbed 11.5%, and management said it will grow double digits in 2026. Remaining performance obligations climbed 12.8% year over year.
Two analysts from Jefferies and DA Davidson have both recently set a price target of $500 on Adobe shares. That represents about 41% upside from the stock price, as of this writing.
With Adobe's forward P/E sitting at less than 15, it has a lot of upside. Continued strong operating results could eventually turn investor sentiment and support multiple expansion while it grows earnings, leading to strong stock returns in 2026.
2. Atlassian (85% implied upside)
Atlassian (NASDAQ: TEAM) develops enterprise software to help businesses plan projects and collaborate effectively. While it initially focused on teams of software engineers, it has since expanded to general use, now serving over 300,000 customers and millions of monthly active users.
The company is currently migrating customers from being able to install its software on their own private data centers to using its cloud-based platform. The migration is going well, and integrating new AI features into the cloud platform has helped accelerate adoption. Management said it has over 3.5 million AI monthly active users, up from 2.3 million in the prior quarter. Cloud revenue climbed 26% last quarter, and remaining performance obligations climbed 42%, indicating a long runway of growth ahead.
The data center business will officially cease operations in March 2029. That will enable Atlassian to focus exclusively on a single platform, reducing its overhead costs. It should also allow it to roll out new features or modules for its software more easily, as it doesn't have to worry about various data center configurations, giving it more opportunities to upsell customers.
Bernstein analyst Peter Weed put a $304 price target on the stock in mid-November after digesting the company's first-quarter earnings. That implies upside of about 85% from the stock price, as of this writing. Considering the rapid top-line growth exceeding 20% per year and the potential for margin expansion, there's a lot of potential for earnings growth going forward. Even at a forward P/E of approximately 32, the stock appears to have sufficient growth potential to justify the price.
3. Marvell Technology (88% implied upside)
Marvell Technology (NASDAQ: MRVL) is a semiconductor company specializing in networking chips and custom AI accelerators. For the latter, it collaborates closely with Microsoft and Amazon on their Maia, Trainium, and Inferentia chips. It also works with other hyperscalers on custom silicon solutions to make the most of the hardware in their data centers.
Shares of the stock took a hit recently when The Information reported Microsoft was exploring a partnership with Broadcom for custom chips. Microsoft is reportedly planning a significant increase in custom silicon purchases once it begins producing the Maia300 chip. Fubon Research said the tech giant plans to buy as much as $12 billion worth of the chip in calendar 2027. That represents a huge amount of potential business for Marvel, which brought in less than $8 billion over the last four quarters.
So, a report that Microsoft might source chips from rival Broadcom is concerning for Marvell, but the truth is, Marvell was unlikely to maintain a monopoly over any hyperscaler's business. To that end, CEO Matt Murphy noted it hasn't lost any business from Microsoft, or Amazon for that matter. Marvell should be able to continue growing quickly thanks to its custom AI accelerator business through 2026 and beyond, as the trend toward custom silicon accelerates.
Evercore ISI analyst Mark Lipacis raised his price target on the stock to $156 earlier this month. That implies upside of about 88% from the stock's price, as of this writing. He views management's strategic moves, such as the recent acquisition of Celestial AI, and its position in custom AI and data center solutions, as keys to sustained growth.
At less than 30 times forward earnings, the stock looks attractive relative to its growth prospects.
Should you buy stock in Marvell Technology right now?
Before you buy stock in Marvell Technology, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Marvell Technology wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $509,039!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,109,506!*
Now, it’s worth noting Stock Advisor’s total average return is 972% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of December 20, 2025.
Adam Levy has positions in Adobe, Amazon, and Microsoft. The Motley Fool has positions in and recommends Adobe, Amazon, Atlassian, Evercore, Jefferies Financial Group, and Microsoft. The Motley Fool recommends Broadcom and Marvell Technology and recommends the following options: long January 2026 $395 calls on Microsoft, long January 2028 $330 calls on Adobe, short January 2026 $405 calls on Microsoft, and short January 2028 $340 calls on Adobe. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

3 Artificial Intelligence Stocks With as Much as 88% Upside in 2026, According to Select Wall Street Analysts

Key Points
From current prices, Brent Thill at Jeffries expects CoreWeave stock to return 128%, and Jeff Cantwell at Seaport Research expects Circle stock to return 245%.
CoreWeave operates a new type of cloud platform purpose-built for AI, and SemiAnalysis recently ranked the company as the top provider of AI cloud services.
Circle develops the USDC stablecoin and an adjacent payments network that supports faster and cheaper transactions than traditional financial systems.
CoreWeave (NASDAQ: CRWV) is already disrupting the cloud services industry with infrastructure purpose-built for artificial intelligence. Circle Internet Group (NYSE: CRCL) hopes to revolutionize the financial services industry by connecting enterprises with its stablecoin network. Certain Wall Street analysts think the stocks are deeply undervalued.
Brent Thill at Jefferies values CoreWeave at $155 per share. That implies 128% upside from its current share price of $68.
Jeff Cantwell at Seaport Research values Circle at $280 per share. That implies 245% upside from its current share price of $81.
Investors should never lean too heavily on target prices, but these stocks are compelling long-term investment ideas. Here's why.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
CoreWeave: Shaping the future of artificial intelligence and cloud computing
CoreWeave is a neocloud, sometimes called an artificial intelligence (AI) cloud or graphics processing unit (GPU) cloud. Regardless of terminology, the company is the leader among an emerging class of cloud services providers whose data center infrastructure is purpose-built for AI workloads like training and inference.
Research company SemiAnalysis recently ranked CoreWeave as the most capable provider of cloud AI services, scoring its platform above technology giants Amazon, Microsoft, and Alphabet. Analyst Dylan Patel wrote, "CoreWeave continues to set the benchmark for AI cloud performance by demonstrating strong technical execution and operational maturity."
CoreWeave reported solid third-quarter financial results. Revenue increased 134% to $1.3 billion on strong demand for AI infrastructure. The company also reported a narrower GAAP loss of $0.22 per diluted share, up from $1.82 per diluted share in the prior year. Finally, cash from operations increased more than 100% to $1.7 billion.
Nevertheless, the stock has fallen 36% since the reported because management lowered its full-year guidance and investors are worried about an AI bubble. Those concerns are overblown. The lower guidance reflects postponed (not lost) revenue due to data center construction delays, and Grand View Research says cloud AI spending will increase at 40% annually through 2030.
CoreWeave stock currently trades at 6.5 times sales. That is very reasonable (if not cheap) for a company whose revenue is projected to increase at 95% annually through 2027. That forecast suggests analysts are confident CoreWeave will keep growing at a rapid clip because of deep customer relationships with AI giants Microsoft, Meta Platforms, and OpenAI. Also, Nvidia has agreed to purchase any unsold compute capacity through April 2032. Investors with a time horizon of at least three years should consider buying a small position.
Circle Internet Group: Shaping the future of global finance
Circle is a fintech company that issues stablecoins and provides software tools that allow developers to integrate digital asset storage and payments into their applications. Its best-known product is USDC, the second largest stablecoin by market value, but the largest one that adheres to stringent regulations in the U.S. and Europe.
Interest payments are the primary source of revenue. USDC tokens are backed by an equal amount of dollar-denominated financial assets like Treasury bills and other government securities. However, the company is expanding into payments with the Circle Payments Network (CPN), which promises faster and cheaper transactions across use cases ranging from employee payroll to e-commerce.
Circle reported encouraging financial results in the third quarter. Revenue increased 66% to $740 million despite a modest reduction in interest rates because the circulating volume of USDC increased 108%. Meanwhile, adjusted EBITDA increased 78% to $166 million.
Management also provided two important updates: First, the CPN now includes 29 financial institutions, with more than 500 potential customers in the pipeline. Second, the company started testing its Arc blockchain, which resolves the problem of unpredictable gas fees on other blockchains.
Looking ahead, stablecoin revenue is projected to increase at 54% annually through 2030. JPMorgan Chase says USDC is the preferred stablecoin among financial institutions because of its focus on regulatory compliance. That makes Circle an attractive long-term investment, especially when the stock trades at 7.6 times sales, nearly the cheapest valuation since its June IPO.
Should you buy stock in CoreWeave right now?
Before you buy stock in CoreWeave, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CoreWeave wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $506,935!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,067,514!*
Now, it’s worth noting Stock Advisor’s total average return is 958% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of December 20, 2025.
JPMorgan Chase is an advertising partner of Motley Fool Money. Trevor Jennewine has positions in Amazon and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, JPMorgan Chase, Jefferies Financial Group, Meta Platforms, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

2 Stocks Shaping the Future of Technology -- They May Soar 128% and 245% in 2026, According to Wall Street Analysts

For Immediate Releases
Chicago, IL – December 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include On Holding AG ONON, Lennar Corp. LEN, Jefferies Financial Group Inc. JEF, Omnicom Group Inc. OMC and Thomson Reuters Corp. TRI.
Here are highlights from Monday’s Analyst Blog:
Buy 5 Non-Tech Stocks on the Dip to Strengthen Your Portfolio in 2026
On Dec. 11, the two major indexes — the Dow and the S&P 500 — have advanced 1.3% and 0.2%, respectively. At the same time, these two benchmarks recorded their fresh all-time high closing. On the other hand, the tech-heavy Nasdaq Composite fell 0.3%.
The recent Fed rate cut and extremely high valuation of the technology sector compelled market participants to shift from technology to other rate-sensitive cyclical sectors, such as utilities, industrials, financials, energy, materials and health care.
At this stage, we recommend five non-tech large-cap stocks that are currently trading on the dip from their 52-week highs and available at attractive valuations. These are: On Holding AG, Lennar Corp., Jefferies Financial Group Inc., Omnicom Group Inc. and Thomson Reuters Corp. Each of our picks currently carries a Zacks Rank b#2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
On Holding AG
On Holding provides footwear and sports apparel products including ultralight and stretchable fabrics and accessories. ONON offers its products through independent retailers and distributors, online and stores.
On Holding has an expected revenue and earnings growth rate of 20.6% and 79.3%, respectively, for next year. The Zacks Consensus Estimate for next year’s earnings has improved 22% over the last 30 days. ONON is currently trading at a discount of 22.7% from its 52-week high.
Lennar Corp.
Lennar is engaged in homebuilding and financial services in the United States. LEN’s prospects are benefiting from its focus on the tech-enabled manufacturing platform, aimed at unlocking scalable efficiencies, reducing customer acquisition costs, and modernizing its entire operating model. Also, an asset-light and land-light model, and playbook strategies, bode well.
LEN is focused on various playbook strategies to reduce the direct construction cost, deliver gross margin improvement and maintain starts for the upcoming quarters. LEN prioritizes collaboration with trade partners to streamline the cost structure according to the prevailing sales price environment, aiming to speed up construction and reduce supply-chain disruptions.
Lennar has an expected revenue and earnings growth rate of 1.9% and 11.1%, respectively, for next year (ending November 2026). The Zacks Consensus Estimate for next year’s earnings has improved 0.2% over the last seven days. LEN is currently trading at a discount of 21.2% from its 52-week high.
Jefferies Financial Group Inc.
Jefferies Financial Group has gained market share in the investment banking (IB) business over the years without commensurately expanding its balance sheet and taking risks. This will likely continue to drive JEF’s top-line expansion as the IB business shows strength. Additionally, strategic collaborations and solid trading and asset management operations are likely to bolster its financials.
JEF’s strategic JVs and partnerships are expected to bolster its financial performance. While JEF faced challenges due to relatively higher interest rates and uncertainties surrounding tariff policies, a changing macroeconomic environment will likely support demand for leveraged loans.
Jefferies Financial Group has an expected revenue and earnings growth rate of 16.5% and 59.5%, respectively, for next year (ending November 2026). The Zacks Consensus Estimate for next year’s earnings has improved 0.8% over the last seven days. JEF is currently trading at a discount of 23.7% from its 52-week high.
Omnicom Group Inc.
Omnicom Group’s diverse portfolio across domains and in both the traditional and digital marketing segments reduces reliance on single revenue streams, ensuring adaptability and stability of revenues.
OMC’s investments in IT, data, analytics, and precision marketing enhance operational efficiency and attract clients with personalized campaigns, supporting growth in the digital advertising space. These efforts of OMC are supplemented with strategic M&A and reorganization efforts that bolster profitability. OMC continues to return value to its shareholders through both repurchases and dividends.
Omnicom Group has an expected revenue and earnings growth rate of 3.1% and 8.8%, respectively, for next year. The Zacks Consensus Estimate for next year’s earnings has improved 2.4% in the last 30 days. OMC is currently trading at a discount of 13.2% from its 52-week high.
Thomson Reuters Corp.
Thomson Reuters is a leading provider of value-added information and technology to users in the fields of law, tax, accounting, financial services, higher education, reference information, corporate training and assessment, scientific research and healthcare. TRI has five segments: Legal Professionals, Corporates, Tax and Accounting Professionals, Reuters News, and Global Print. TRI operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Thomson Reuters has an expected revenue and earnings growth rate of 7.6% and 12.4%, respectively, for next year. The Zacks Consensus Estimate for next year’s earnings has improved 2.1% in the last 60 days. TRI is currently trading at a discount of 39.6% from its 52-week high.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Analyst Blog On Holding, Lennar, Jefferies, Omnicom and Thomson

On Dec. 11, the two major indexes — the Dow and the S&P 500 — have advanced 1.3% and 0.2%, respectively. At the same time, these two benchmarks recorded their fresh all-time high closing. On the other hand, the tech-heavy Nasdaq Composite fell 0.3%.
The recent Fed rate cut and extremely high valuation of the technology sector compelled market participants to shift from technology to other rate-sensitive cyclical sectors, such as utilities, industrials, financials, energy, materials and health care.
At this stage, we recommend five non-tech large-cap stocks that are currently trading on the dip from their 52-week highs and available at attractive valuations. These are: On Holding AG ONON, Lennar Corp. LEN, Jefferies Financial Group Inc. JEF, Omnicom Group Inc. OMC and Thomson Reuters Corp. TRI. Each of our picks currently carries a Zacks Rank b#2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The chart below shows the price performance of our five picks year to date.
Image Source: Zacks Investment Research
On Holding AG
On Holding provides footwear and sports apparel products including ultralight and stretchable fabrics and accessories. ONON offers its products through independent retailers and distributors, online and stores.
On Holding has an expected revenue and earnings growth rate of 20.6% and 79.3%, respectively, for next year. The Zacks Consensus Estimate for next year’s earnings has improved 22% over the last 30 days. ONON is currently trading at a discount of 22.7% from its 52-week high.
Lennar Corp.
Lennar is engaged in homebuilding and financial services in the United States. LEN’s prospects are benefiting from its focus on the tech-enabled manufacturing platform, aimed at unlocking scalable efficiencies, reducing customer acquisition costs, and modernizing its entire operating model. Also, an asset-light and land-light model, and playbook strategies, bode well.
LEN is focused on various playbook strategies to reduce the direct construction cost, deliver gross margin improvement and maintain starts for the upcoming quarters. LEN prioritizes collaboration with trade partners to streamline the cost structure according to the prevailing sales price environment, aiming to speed up construction and reduce supply-chain disruptions.
Lennar has an expected revenue and earnings growth rate of 1.9% and 11.1%, respectively, for next year (ending November 2026). The Zacks Consensus Estimate for next year’s earnings has improved 0.2% over the last seven days. LEN is currently trading at a discount of 21.2% from its 52-week high.
Jefferies Financial Group Inc.
Jefferies Financial Group has gained market share in the investment banking (IB) business over the years without commensurately expanding its balance sheet and taking risks. This will likely continue to drive JEF’s top-line expansion as the IB business shows strength. Additionally, strategic collaborations and solid trading and asset management operations are likely to bolster its financials.
JEF’s strategic JVs and partnerships are expected to bolster its financial performance. While JEF faced challenges due to relatively higher interest rates and uncertainties surrounding tariff policies, a changing macroeconomic environment will likely support demand for leveraged loans.
Jefferies Financial Group has an expected revenue and earnings growth rate of 16.5% and 59.5%, respectively, for next year (ending November 2026). The Zacks Consensus Estimate for next year’s earnings has improved 0.8% over the last seven days. JEF is currently trading at a discount of 23.7% from its 52-week high.
Omnicom Group Inc.
Omnicom Group’s diverse portfolio across domains and in both the traditional and digital marketing segments reduces reliance on single revenue streams, ensuring adaptability and stability of revenues.
OMC’s investments in IT, data, analytics, and precision marketing enhance operational efficiency and attract clients with personalized campaigns, supporting growth in the digital advertising space. These efforts of OMC are supplemented with strategic M&A and reorganization efforts that bolster profitability. OMC continues to return value to its shareholders through both repurchases and dividends.
Omnicom Group has an expected revenue and earnings growth rate of 3.1% and 8.8%, respectively, for next year. The Zacks Consensus Estimate for next year’s earnings has improved 2.4% in the last 30 days. OMC is currently trading at a discount of 13.2% from its 52-week high.
Thomson Reuters Corp.
Thomson Reuters is a leading provider of value-added information and technology to users in the fields of law, tax, accounting, financial services, higher education, reference information, corporate training and assessment, scientific research and healthcare. TRI has five segments: Legal Professionals, Corporates, Tax and Accounting Professionals, Reuters News, and Global Print. TRI operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Thomson Reuters has an expected revenue and earnings growth rate of 7.6% and 12.4%, respectively, for next year. The Zacks Consensus Estimate for next year’s earnings has improved 2.1% in the last 60 days. TRI is currently trading at a discount of 39.6% from its 52-week high.
Zacks Naming Top 10 Stocks for 2026
Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.
From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Buy 5 Non-Tech Stocks on the Dip to Strengthen Your Portfolio in 2026

Key Points
Stock splits in high-profile companies have piqued the interest of retail investors and Wall Street professionals this year.
The market's blockbuster stock split of 2025 can soar 55% in the new year, based on the projections from one Wall Street analyst.
Meanwhile, the highest-profile reverse split could rise by triple digits, but it has an undeniably bumpy road ahead.
Since the beginning of 2023, no innovation has garnered more attention on Wall Street than the rise of artificial intelligence (AI). However, AI isn't the only trend that's been lifting the stock market's tide. Investor euphoria regarding stock splits in influential businesses has played an important role in fueling optimism on Wall Street.
In 2025, five brand-name companies have taken the plunge and completed splits, including Netflix (NASDAQ: NFLX), O'Reilly Automotive (NASDAQ: ORLY), Lucid Group (NASDAQ: LCID), Fastenal (NASDAQ: FAST), and Interactive Brokers Group (NASDAQ: IBKR).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
A stock split is a tool publicly traded companies have at their disposal to cosmetically adjust their share price and outstanding share count by the same factor. These changes are purely superficial in the sense that they don't affect a company's market cap or operating performance.
In addition to piquing the interest of everyday investors, stock splits can also garner the attention of Wall Street professionals. Based on the high-water price targets of select Wall Street analysts, two of the aforementioned five high-profile stock-split stocks offer up to 135% upside in 2026.
Netflix: Implied upside of 55%
The first high-flying stock-split stock that at least one Wall Street analyst believes can soar in the new year is streaming services provider Netflix, which completed a 10-for-1 forward split in mid-November.
On July 18, Jefferies analyst James Hawley kept his firm's buy rating on Netflix stock but upped the price target to $1,500, which is now a split-adjusted $150 per share and represents 55% upside from where shares closed on Dec. 8. In the research note, Hawley highlighted that North American sales growth (U.S. and Canada) has jumped to 15% from 9%, which suggests customer churn remains low, even as the company has increased its prices.
The note also adds that Netflix can grow its earnings per share (EPS) by more than 20% annually over the next three to five years.
There's little question that Netflix continues to ride its first-mover advantage to substantial profits. It's overseen more original content releases than any of its peers, with shows like Stranger Things and Squid Game attracting new subscribers and ensuring existing customers remain within its ecosystem.
Netflix has also been successful with its innovation beyond the big screen. A little over three years ago, the company introduced an advertising-based tier as a more affordable option for its streaming subscribers. As of May 2025, approximately 94 million people had signed up for this ad-driven option.
Likewise, Netflix finally cracked down on password-sharing in May 2023 by requiring that accounts remain within a single household. The solutions offered by the company, which include paying for an extra member or having people outside the household set up a paid account in their name, have boosted total subscribers and profitability.
But it's not clear if Netflix shares can reach this lofty price target in 2026, given its recently announced deal to acquire Warner Bros. Discovery, following the separation of Discovery Global, for $82.7 billion, which works out to $23.25 per share in cash and $4.50 per share in Netflix stock.
On paper, the deal makes plenty of sense, with Netflix gaining access to HBO and HBO Max, as well as Warner Bros.' valuable studio segment. However, serious antitrust questions will arise from this deal, which could cast a grey cloud above the company's stock throughout much of 2026. While this doesn't mean the deal won't get done, the legal and profit-driven uncertainties associated with this buyout may weigh on Netflix for the foreseeable future.
Lucid Group: Implied upside of 135%
Whereas Netflix, O'Reilly Automotive, Fastenal, and Interactive Brokers Group all completed forward splits this year, electric-vehicle (EV) maker Lucid Group was the most-hyped reverse split of 2025. Its 1-for-10 reverse split, which lifted its share price from around $2 to closer to $20, went into effect in early September.
Investors typically gravitate toward public companies announcing and completing forward splits, and shy away from businesses that undertake reverse splits. Companies that need to increase their share price are often struggling on an operating basis and splitting their shares to avoid delisting from a major stock exchange.
Despite what history tells us, Benchmark's Mickey Legg has an optimistic view of Lucid Group stock for 2026. Even though he lowered his firm's price target on the company this year, the $30 Legg expects for Lucid shares would imply upside of 135%!
Legg's optimism for Lucid crescendoed in mid-July, which is when Lucid announced a partnership with Uber Technologies and privately held Nuro to launch a global robotaxi program. Lucid will be responsible for delivering 20,000 (or more) of its Gravity SUVs over six years.
However, Lucid has endured several missteps during its attempted production ramp-up, to the point where it's becoming difficult for investors to believe management's growth and production forecasts.
With Tesla moving away from its luxury Model S to mass-produce the more affordable Model 3 sedan, the luxury EV space was ripe for the taking. But due to a myriad of supply chain issues that coincided with and followed the COVID-19 pandemic, Lucid Air sedan production and delivery figures have been a major disappointment. While management had predicted 90,000 units of production for 2024 when the company went public in 2021, guidance had fallen to just 9,000 units of production by the time 2024 arrived.
Lucid also missed its opportunity with Gravity. Initially, the company's SUV was expected to hit showroom floors in 2024. This launch was eventually delayed until the spring of this year.
Perhaps the biggest snag in Legg's optimistic price target is Lucid's balance sheet. Although the company has received billions of dollars in backing from Saudi Arabia's Public Investment Fund, it's been burning cash and losing money at an extraordinary rate. It's burned through more than $2 billion in cash from its operating activities in the first nine months of 2025 and has lost close to $14.8 billion since the company was incepted.
Building an EV company from the ground up to mass production is a costly and time-consuming process. Lucid Group hasn't yet demonstrated that it possesses the necessary tools or intangibles to succeed, which makes it unlikely that Legg's lofty price target will be achieved in 2026.
Should you invest $1,000 in Netflix right now?
Before you buy stock in Netflix, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Netflix wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $521,550!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,133,904!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of December 8, 2025
Sean Williams has positions in Warner Bros. Discovery. The Motley Fool has positions in and recommends Interactive Brokers Group, Jefferies Financial Group, Netflix, Tesla, Uber Technologies, and Warner Bros. Discovery. The Motley Fool recommends the following options: long January 2027 $43.75 calls on Interactive Brokers Group and short January 2027 $46.25 calls on Interactive Brokers Group. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

2 Stock-Split Stocks With Up to 135% Upside in 2026, According to Select Wall Street Analysts

Key Points
The biotech announced a secondary stock issue.
It aims to sell $300 million worth of common shares.
It isn't unusual for a biotech to raise capital after it posts positive results from a clinical trial. In the case of a new fundraising effort by Dyne Therapeutics (NASDAQ: DYN), however, investors aren't happy that the biotech is going to the well. Following the announcement of a significant secondary stock issue, market players traded out of Dyne on Tuesday, leaving its shares with a nearly 17% loss.
300 million reasons for concern
Just after market close on Monday, Dyne announced that it has launched an underwritten public offering of $300 million worth of its common stock. The underwriters of the issue, which include Morgan Stanley and Jefferies, have been granted a 30-day option to collectively purchase up to an additional $45 million.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
In its offering prospectus, Dyne stated that it intends to use its share of the proceeds to advance its development programs. This comes on the heels of its successful phase 1/2 clinical trial for Duchenne muscular dystrophy (DMD) treatment zeleciment rostudirsen.
It also aims to build manufacturing assets for drugs it may win approval for in the future. It will also spend the funds on "working capital and other general corporate purposes."
The dilution problem
That $300 million to $345 million in new capital is going to be dilutive, given that Dyne's current market cap is a shade over $2.6 billion. Investors dislike share dilution, and they become quite uncomfortable when it reaches double-digit percentages.
While Tuesday's market reaction was understandable, then, Dyne has some good momentum with zeleciment rostudirsen, and the drug has much promise if it can eventually earn regulatory approval. If I were a Dyne shareholder, I'd stay the course with the stock and not be overly concerned with dilution.
Should you invest $1,000 in Dyne Therapeutics right now?
Before you buy stock in Dyne Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dyne Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $521,982!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,137,459!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of December 8, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Jefferies Financial Group. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Why Dyne Therapeutics Stock Tanked on Tuesday

(RTTNews) - Jefferies Financial Group Inc. (JEF), an investment banking and capital markets firm, Monday announced that it is acquiring a 50 percent stake in Hildene Holding Company, LLC, an asset management company.
Previously, the company was in a strategic relationship with Hildene in 2022 with Jefferies owning a revenue share in Hildene's asset-management business. Jefferies will exchange its revenue share, a portion of its interest in a Hildene-managed private fund and $340 million in cash for its 50 percent interest in Hildene.
The transaction is expected to close in the third quarter of 2026 and Jefferies is expecting its investment in Hildene to be accretive immediately and to contribute to its net earnings consistently. The company also expects to record around $75 million pretax gain from the markup to fair market value of its pre-transaction interest in Hildene.
Jefferies cash investment in Hildene will be funded by $500 million reduction in the course of 2026 in Jefferies' investment in certain platforms and strategies in its Leucadia Asset Management division.
Coincidentally, Hildene has agreed to acquire SILAC, Inc., the parent company of SILAC Insurance Company, for $550 million in cash.
Jefferies will not consolidate Hildene or SILAC and will account for its investment using the equity method, whereby it will record its 50% share of Hildene's consolidated earnings, the company said in a statement.
In pre-market activity, JEF shares were trading at $60.41, up 2.18% on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Index	Bulls	Bears
Confidence		—
Support		—
Cash flows		—

Jefferies Financial Group Inc.

Market sentiment

Overall assessment

Share of longs and shorts

Long

Short